Paratek Appoints Dennis Molnar as CEO and Evan Loh as Chair – Private Equity Hub

Posted on May 29, 2012 by qiyuan

Additional programs at Paratek include a narrow spectrum tetracycline-derived small molecule optimized for acne and rosacea with a Phase 2 trial planned to begin later this year and preclinical programs for non-infective applications of the …

This entry was posted in News. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

CAPTCHA Image

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>